Skip to content

13F-HR filed by Commodore Capital LP

Commodore Capital LP filed this 13F-HR for the quarter ended 2021-09-30, filed 2021-11-15, with 29 holding rows worth $379,293,000.

Accession
0001831942-21-000008
Filed
2021-11-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2021

A holdings report, 29 entries on the cover page, a total value of $379,293,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $379,293,000 with VALUE read as thousands by filing date, 13F file number 028-20976. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
IVERIC BIO INC46583P102COM2,750,137$44,662,000thousands by filing date
ACLARIS THERAPEUTICS INC COM00461U105Stock2,190,291$39,425,000thousands by filing date
CYTOKINETICS INC23282W605COM NEW796,578$28,470,000thousands by filing date
DICERNA PHARMACEUTICALS INC253031108COM1,292,251$26,052,000thousands by filing date
C4 THERAPEUTICS INC12529R107COM STK481,094$21,495,000thousands by filing date
KURA ONCOLOGY INC COM50127T109Stock999,433$18,719,000thousands by filing date
CELCUITY INC15102K100COM920,464$16,568,000thousands by filing date
COGENT BIOSCIENCES INC19240Q201COM1,912,511$16,084,000thousands by filing date
MERUS N VN5749R100COM718,136$15,799,000thousands by filing date
CYMABAY THERAPEUTICS INC23257D103COM4,169,896$15,220,000thousands by filing date
SATSUMA PHARMACEUTICALS INC80405P107COM3,118,761$14,533,000thousands by filing date
VISTAGEN THERAPEUTICS INC92840H202COM5,123,509$14,038,000thousands by filing date
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW248,207$13,401,000thousands by filing date
VIRIDIAN THERAPEUTICS INC92790C104COM667,674$10,983,000thousands by filing date
TENAYA THERAPEUTICS INC87990A106COM513,930$10,613,000thousands by filing date
IOVANCE BIOTHERAPEUTICS INC462260100COM362,869$8,948,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock579,432$8,854,000thousands by filing date
PROTAGONIST THERAPEUTICS74366E102COM498,079$8,826,000thousands by filing date
KRONOS BIO INC50107A104COM298,839$6,264,000thousands by filing date
REVOLUTION MEDICINES INC COM76155X100Stock226,228$6,224,000thousands by filing date
GENOCEA BIOSCIENCES INC372427401COMMON STOCK3,079,756$5,913,000thousands by filing date
KALVISTA PHARMACEUTICALS INC483497103COM312,553$5,454,000thousands by filing date
DYNE THERAPEUTICS INC COM26818M108Stock305,125$4,955,000thousands by filing date
MEREO BIOPHARMA GROUP PLC589492107CMN1,972,958$4,775,000thousands by filing date
PMV PHARMACEUTICALS INC69353Y103COM125,000$3,725,000thousands by filing date
INVENTIVA SA46124U107ADS262,658$3,719,000thousands by filing date
BCLS ACQUISITION CORPG0904B105CMN250,000$2,490,000thousands by filing date
ASTRIA THERAPEUTICS INC COM04635X102Stock239,270$2,115,000thousands by filing date
ARS PHARMACEUTICALS INC82835W108COM97,143$969,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001831942-21-000008this filing2021-11-15acceptance time not in the bulk data set